Recombinant multi-species NMNAT2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NMNAT2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene product belongs to the nicotinamide mononucleotide adenylyltransferase (NMNAT) enzyme family, members of which catalyze an essential step in NAD (NADP) biosynthetic pathway. Unlike the other human family member, which is localized to the nucleus, and is ubiquitously expressed; this enzyme is cytoplasmic, and is predominantly expressed in the brain. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
The Alternative Names of target: C1orf15,D030041I09Rik,NMN/NaMN adenylyltransferase 2,NMNAT2,Nicotinamide mononucleotide adenylyltransferase 2 (NMN adenylyltransferase 2),Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2,Nicotinate-nucleotide adenylyltransferase 2 (NaMN adenylyltransferase 2),Nmnat2,PNAT1,PNAT2
Go
to NMNAT2 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP6701-Ag-1/ GM-Tg-hg-IP6701-Ag-2 | Human NMNAT2 protein | Human |
| GM-Tg-rg-IP6701-Ag-1/ GM-Tg-rg-IP6701-Ag-2 | Rat NMNAT2 protein | Rat |
| GM-Tg-mg-IP6701-Ag-1/ GM-Tg-mg-IP6701-Ag-2 | Mouse NMNAT2 protein | Mouse |
| GM-Tg-cynog-IP6701-Ag-1/ GM-Tg-cynog-IP6701-Ag-2 | Cynomolgus/Rhesus macaque NMNAT2 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP6701-Ag-1/ GM-Tg-felg-IP6701-Ag-2 | Feline NMNAT2 protein | Feline |
| GM-Tg-cang-IP6701-Ag-1/ GM-Tg-cang-IP6701-Ag-2 | Canine NMNAT2 protein | Canine |
| GM-Tg-bovg-IP6701-Ag-1/ GM-Tg-bovg-IP6701-Ag-2 | Bovine NMNAT2 protein | Bovine |
| GM-Tg-equg-IP6701-Ag-1/ GM-Tg-equg-IP6701-Ag-2 | Equine NMNAT2 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP6701-Ag-1/ GM-Tg-hg-IP6701-Ag-2;
GM-Tg-rg-IP6701-Ag-1/ GM-Tg-rg-IP6701-Ag-2;
GM-Tg-mg-IP6701-Ag-1/ GM-Tg-mg-IP6701-Ag-2; GM-Tg-cynog-IP6701-Ag-1/ GM-Tg-cynog-IP6701-Ag-2; GM-Tg-felg-IP6701-Ag-1/ GM-Tg-felg-IP6701-Ag-2; GM-Tg-cang-IP6701-Ag-1/ GM-Tg-cang-IP6701-Ag-2; GM-Tg-bovg-IP6701-Ag-1/ GM-Tg-bovg-IP6701-Ag-2; GM-Tg-equg-IP6701-Ag-1/ GM-Tg-equg-IP6701-Ag-2 |
| Products Name | NMNAT2 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | NMNAT2 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NMNAT2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.